DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Maxim Shemetov - 1 Uzhuralzoloto - 1 Vladimir Putin's - 1 Softline - 1 Alexander Marrow - 1 Kevin Liffey - 1 Amyris - 1 Han Kieftenbeld - 1
Top related locs:
Bengaluru Moscow Russia Ukraine IPOs U.S Delaware Spain
Top related orgs:
Thomson - 5 Biotech - 3 Henderson - 1 REUTERS - 1 SmartTechGroup - 1 Technology - 1 Astra - 1 SPO - 1

Search resuls for: "- Biotech"


7 mentions found


☆ Russian companies' scaled-down IPOs in 2023
  + stars: | 2023-11-13 | by ( ) www.reuters.com   time to read: +2 min
A customer walks in a store of Russian clothing retailer Henderson in Moscow, Russia October 31, 2023. IPO/DPO- Biotech startup Genetico (GECO.MM) raised 179 million roubles in an IPO in April. - CarMoney, a fintech service owned by SmartTechGroup (STG) raised 978 million roubles in a direct public offering (DPO) in July. - Technology company Astra (ASTR.MM) raised 3.5 billion roubles in an October IPO. - Men's clothing chain Henderson (HNFG.MM) attracted 3.8 billion roubles through its IPO in early November.
Persons: Maxim Shemetov, Uzhuralzoloto, Vladimir Putin's, Softline, Alexander Marrow, Kevin Liffey Organizations: Henderson, REUTERS, Biotech, SmartTechGroup, Technology, Astra, SPO, State, VTB Bank, Reuters, Thomson Locations: Moscow, Russia, Ukraine, IPOs
☆ Biotech firm Amyris files for bankruptcy in US
  + stars: | 2023-08-10 | by ( ) www.reuters.com   time to read: +1 min
Aug 9 (Reuters) - Biotech firm Amyris Inc (AMRS.O) on Wednesday said it has filed for Chapter 11 bankruptcy in a U.S. court and is planning to sell its consumer brands to improve the company's liquidity position. Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings. In a filing with the Delaware bankruptcy court, the company listed estimated assets in the range of $500 million to $1 billion and liabilities in the range of $1 billon to $10 billion. "Restructuring is intended to improve the Company's cost structure, capital structure, and liquidity position while streamlining Amyris' business portfolio to focus on its core competencies in R&D...," the company said. Amyris had also initiated a "strategic transformation program" in June and secured a term loan facility of up to $50 million.
Persons: Amyris, Han Kieftenbeld, John Melo, Juby Babu, Rashmi Organizations: Biotech, Amyris Inc, Thomson Locations: U.S, Delaware, Bengaluru
☆ Biotech’s doldrums are a warning amid exuberance
  + stars: | 2023-07-25 | by ( ) www.reuters.com   time to read: +2 min
The sector’s doldrums are a warning sign, despite the broader market shrugging off recession concerns. In 2000, the index peaked weeks before the S&P 500 Index (.SPX) and hit bottom three months earlier. In the 2009 financial crisis, the biotech index peaked later, but both emerged at about the same time. Yet biotech stocks have been lackluster since. Since January, the index is down 2%, while the S&P 500 Index is up 19% and the Nasdaq Composite Index is up 35%.
Persons: Robert Cyran, Jonathan Guilford, Sharon Lam Organizations: YORK, Reuters, Biotechnology, Nasdaq Biotechnology, Nasdaq, Twitter, Thales, Thomson Locations: Spain
☆ Roivant in talks to sell bowel disease drug to Roche in over $7 bln deal - WSJ
  + stars: | 2023-07-13 | by ( ) www.reuters.com   time to read: +1 min
July 13 (Reuters) - Biotech company Roivant Sciences (ROIV.O) is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease to Roche (ROG.S) in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday. The sale of the drug could be announced in the coming days, the report said, citing people familiar with the matter. Roivant's experimental drug, RVT-3101, is under clinical trials for the treatment of moderate-to-severe ulcerative colitis, a long-term condition where the colon and rectum become inflamed, as well as a type of inflammatory bowel disease known as Crohn's disease. Roivant declined to comment, whereas Roche did not immediately respond to a Reuters request for comment. Reporting by Shivani Tanna and Sriparna Roy in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
Persons: Roche, Roivant, Shivani Tanna, Sriparna Roy, Shailesh Organizations: - Biotech, Roivant Sciences, Wall Street, Thomson Locations: Bengaluru
☆ Biotech firm Tevogen Bio enters $1.2 bln SPAC deal for US listing
  + stars: | 2023-06-29 | by ( ) www.reuters.com   time to read: +1 min
June 29 (Reuters) - Biotech firm Tevogen Bio will go public in the United States through a blank-check merger that values the combined entity at about $1.2 billion, the companies said on Thursday. The deal with Semper Paratus Acquisition (LGST.O) will help Tevogen speed up the development of its COVID-19 therapy, TVGN 489. A special-purpose acquisition company (SPAC), also known as a "blank-check firm," is a listed entity that merges with a private firm to take it public. Such shell companies help private firms avoid the longer route of an initial public offering for going public. Reporting by Manya Saini and and Pritam Biswas in Bengaluru Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.
Persons: SPACs, Manya Saini, Pritam Biswas, Vinay Dwivedi Organizations: Biotech, Semper, Holdings, New York Stock Exchange, Thomson Locations: United States, Bengaluru
☆ Roivant, Pfizer team up on inflammatory disease drug
  + stars: | 2022-12-01 | by ( Bhanvi Satija Khushi Mandowara | Bhanvi Satija | Khushi Mandowara | ) www.reuters.com   time to read: +2 min
Dec 1 (Reuters) - Biotech firm Roivant Sciences (ROIV.O) on Thursday launched a company with Pfizer Inc (PFE.N) focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market. The drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest. SVB Securities analyst David Risinger says the deal shows how Pfizer is prioritizing research spending for its oral ulcerative colitis drug, etrasimod, which holds a near-term blockbuster opportunity. RVT-3101 could represent a nearly $15 billion commercial opportunity in the United States for Roivant as a treatment for both ulcerative colitis and Crohn’s disease, said Risinger. Pfizer has also licensed its inflammatory autoimmune disease drug brepocitinib to Roivant in exchange for a 25% stake in another jointly held company called Priovant.
☆ Biotech firm Prime Medicine valued at $1.8 bln in strong debut
  + stars: | 2022-10-20 | by ( ) www.reuters.com   time to read: +2 min
Oct 20 (Reuters) - Biotechnology firm Prime Medicine (PRME.O) notched a valuation of about $1.8 billion in its Nasdaq debut on Thursday, braving tough market conditions that have forced several IPO-bound companies to slam the breaks on their listing plans. Shares of Prime Medicine started trading nearly 12% above their IPO price of $17 each. Its investors include Alphabet Inc's (GOOGL.O) GV, Newpath Partners, Moore Strategic Ventures and Samsara Biocapital, the firm's website showed. Prime Medicine sold 10.3 million shares in its upsized offering, raising $175 million in proceeds priced at $17 apiece, the midpoint of its proposed range of $16 and $18 per share. Register now for FREE unlimited access to Reuters.com RegisterReporting by Manya Saini in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 7